New ACTICOAT(TM) Silver Coated Anti-microbial Barrier Dressing Receives 510(k) Clearance from the US FDA

NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and the Advanced Wound Management division of Smith & Nephew plc announced today that the US Food & Drug Administration (FDA) granted marketing clearance for Acticoat(TM) Flex. Acticoat(TM) Flex is an antimicrobial barrier dressing designed to conform to body contours and allow for flexible movement for injuries that require sustained antimicrobial activity. Acticoat(TM) Flex represents a new addition to the Acticoat(TM) family and is coated with NUCRYST's patented SILCRYST(TM) nanocrystalline silver technology.

"We are pleased that the US FDA has granted marketing clearance for Acticoat(TM) Flex," said David B. Holtz, Interim President and Chief Executive Officer, and Chief Financial Officer of NUCRYST.

Published: 29 July 2009
Written by Editor
TSX   Healthcare   FDA HC Decision   Up on News  
Read more: Nucryst Pharmaceuticals Corp ( NCS )

Elron Group Company Medingo Receives Informal Clearance Notice from FDA to Market Its Insulin MicroPump in the United States

Elron Electronic Industries Ltd. (NASDAQ: ELRN) (TASE: ELRN.TA) today announced that Medingo Ltd., a group company held 92% by Elron and its subsidiary RDC – Rafael Development Corporation Ltd., has received an informal notice, by electronic mail, that the Food and Drug Administration ("FDA") has granted clearance to market its Solo™ MicroPump Insulin Delivery System in the United States. A formal and detailed letter from the FDA has not yet been received. Elron will issue an immediate release once a formal letter is received.

Elron Electronic Industries Ltd. (NASDAQ: ELRN) (TASE: ELRN.TA), a member of the IDB Holding group, is a high-technology holding company traded in the Nasdaq and in the Tel-Aviv Stock Exchange.

Published: 28 July 2009
Written by Editor
Nasdaq   Healthcare   FDA HC Decision   Up on News  
Read more: Elron Electronic Industries Ltd ( ELRN )

Agilent Technologies to Acquire Varian, Inc. for $1.5 Billion

Transformational Transaction Establishes Agilent’s Position as a Leading Provider of Analytical Instrumentation to the Applied and Life Sciences Markets

  • Varian had annual revenue of $1 billion in its fiscal year 2008 in a product portfolio that includes lab instrumentation and consumables.
  • Transaction expands Agilent product and application breadth in industrial and life sciences markets; establishes entry into nuclear magnetic resonance (NMR), imaging and vacuum technology markets.
  • Price reflects a premium of approximately 35% to Varian shareholders.
  • All-cash transaction is expected to be accretive to Agilent earnings on a non-GAAP basis in the first full year following completion.
    Published: 27 July 2009
    Written by Editor
    Nasdaq   Healthcare   M & A   Up on News  
    Read more: Varian Inc ( VARI )

Affymetrix Reports Second Quarter 2009 Results -- Company reports total revenue of $81.6 million and net income of $7.3 million

Affymetrix Inc., (Nasdaq: AFFX) today reported its operating results for the second quarter of 2009. Total revenue for the quarter was $81.6 million, as compared to total revenue of $86.9 million in the second quarter of 2008. The negative currency impact for the quarter was $3.0 million.

Product revenue was $67.2 million, which consisted of consumable (array and reagent) revenue of $62.2 million and instrument revenue of $5.0 million. Service revenue was $12.2 million, and royalties and other revenue were $2.2 million. This compares to second quarter 2008 product revenue of $75.0 million, service revenue of $9.0 million, and royalties and other revenue of $2.9 million.

Published: 23 July 2009
Written by Editor
Nasdaq   Healthcare   Financial Results   Up on News  
Read more: Affymetrix Inc ( AFFX )

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

Cardica, Inc. (Nasdaq: CRDC) today announced that the full results of the PAS-Port system multi-center pivotal trial, known as the EPIC trial, were published in the July issue of the peer-reviewed publication The Journal of Thoracic and Cardiovascular Surgery. The PAS-Port system, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2008, creates a secure connection, or anastomosis, between a vein graft and the aorta, the main artery in the human body, during coronary artery bypass grafting (CABG) procedures.

"The data published this month confirm that the PAS-Port system produces comparable patency, saves approximately five minutes per connection and eliminates the need to clamp the aorta required for hand-sewn connections," commented John D. Puskas, M.D., chief of cardiac surgery at Emory Crawford Long Hospital in Atlanta and principal investigator of the EPIC trial. "Overall, Cardica's PAS-Port system provides a safe and reliable alternative to hand-sewing vessels during CABG procedures."

Published: 22 July 2009
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Cardica Inc ( CRDC )
  1. Novadaq(R) Technologies Inc ( NDQ )
  2. Trinity Biotech plc ( TRIB )
  3. BioSyntech Inc ( BSY )
  4. STAAR Surgical Company ( STAA )
  5. Angiotech Pharmaceuticals Inc ( ANP / ANPI )
Copyright © 2025 Stock Junction. All Rights Reserved.